1193 related articles for article (PubMed ID: 18585501)
1. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
2. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.
Payá E; Marín F; González J; Gimeno JR; Feliu E; Romero A; Ruiz-Espejo F; Roldán V; Climent V; de la Morena G; Valdés M
J Card Fail; 2008 Jun; 14(5):414-9. PubMed ID: 18514934
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling.
Rudolph A; Abdel-Aty H; Bohl S; Boyé P; Zagrosek A; Dietz R; Schulz-Menger J
J Am Coll Cardiol; 2009 Jan; 53(3):284-91. PubMed ID: 19147047
[TBL] [Abstract][Full Text] [Related]
4. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
Orn S; Manhenke C; Squire IB; Ng L; Anand I; Dickstein K
J Card Fail; 2007 Dec; 13(10):843-9. PubMed ID: 18068618
[TBL] [Abstract][Full Text] [Related]
5. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
6. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling.
Saura D; Marín F; Climent V; González J; Roldán V; Hernández-Romero D; Oliva MJ; Sabater M; de la Morena G; Lip GY; Valdés M
Int J Clin Pract; 2009 Oct; 63(10):1465-71. PubMed ID: 19769703
[TBL] [Abstract][Full Text] [Related]
7. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy.
Romero-Puche A; Marín F; González-Carrillo J; García-Honrubia A; Climent V; Feliu E; Ruiz-Espejo F; Payá E; Gimeno-Blanes JR; de la Morena G; Valdés-Chavarri M
Rev Esp Cardiol; 2008 Aug; 61(8):853-60. PubMed ID: 18684368
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy.
Moreno V; Hernández-Romero D; Vilchez JA; García-Honrubia A; Cambronero F; Casas T; González J; Martínez P; Climent V; de la Morena G; Valdés M; Marín F
J Card Fail; 2010 Dec; 16(12):950-6. PubMed ID: 21111984
[TBL] [Abstract][Full Text] [Related]
10. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
11. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
12. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction.
Tziakas DN; Chalikias GK; Hatzinikolaou EI; Stakos DA; Tentes IK; Kortsaris A; Hatseras DI; Kaski JC
Am J Cardiol; 2005 Jul; 96(1):31-4. PubMed ID: 15979428
[TBL] [Abstract][Full Text] [Related]
13. Plasma metalloproteinase levels and left ventricular remodeling in hypertrophic cardiomyopathy in patients with an identical mutation.
Kitaoka H; Kubo T; Okawa M; Takenaka N; Baba Y; Yamasaki N; Matsumura Y; Furuno T; Doi YL
J Cardiol; 2011 Nov; 58(3):261-5. PubMed ID: 21890325
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy.
Ohtsuka T; Nishimura K; Kurata A; Ogimoto A; Okayama H; Higaki J
J Card Fail; 2007 Nov; 13(9):752-8. PubMed ID: 17996824
[TBL] [Abstract][Full Text] [Related]
15. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy.
Münch J; Avanesov M; Bannas P; Säring D; Krämer E; Mearini G; Carrier L; Suling A; Lund G; Patten M
J Card Fail; 2016 Oct; 22(10):845-50. PubMed ID: 27018569
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy].
Dumont CA; Monserrat L; Soler R; Rodríguez E; Fernández X; Peteiro J; Bouzas B; Piñón P; Castro-Beiras A
Rev Esp Cardiol; 2007 Jan; 60(1):15-23. PubMed ID: 17288951
[TBL] [Abstract][Full Text] [Related]
17. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
18. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
Magga J; Sipola P; Vuolteenaho O; Risteli J; Jääskeläinen P; Peuhkurinen K; Kuusisto J
Am J Cardiol; 2008 Apr; 101(8):1185-90. PubMed ID: 18394456
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy.
Cambronero F; Vilchez JA; García-Honrubia A; Ruiz-Espejo F; Moreno V; Hernández-Romero D; Bonacasa B; González-Conejero R; de la Morena G; Martínez P; Climent V; Valdés M; Marín F
Thromb Res; 2010 Jul; 126(1):e46-50. PubMed ID: 20156645
[TBL] [Abstract][Full Text] [Related]
20. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
